Uppsala, Sweden, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced an agreement with Regeneron Genetics Center® (RGC) focused on the use and development of Olink High-Plex offerings as a proteomics platform of choice, with a goal of generating proteomic data at scale to augment RGC’s vast genomics information store. RGC is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics to ultimately improve patient outcomes.
The combination of RGC’s genomics capabilities with Olink’s proteomics platform aims to enable RGC to drive new advances in precision medicine by allowing for a more complete understanding of complex disease mechanisms, discovery of new biomarkers, and potential identification of new therapeutic targets. The platform strives to expand the understanding of protein pathways and disease biology, thereby improving the efficiency of target discovery and downstream drug development.
“The goal of our agreement is to optimize the Olink® Explore platform’s ability to integrate with our existing sequencing infrastructure to seamlessly enable a new layer of actionable data that lies closest to the phenotype. We have already seen early signs that layering proteomic data on top of our traditional methods using genomics is providing increased confidence in what we hypothesize,” said John Overton, Ph.D., Vice President and Chief Sequencing Officer of Regeneron Genetics Center. “RGC hopes that further development and use of the Olink® Explore platform through this agreement will help to unlock a deeper understanding of the underlying biology of disease, in turn informing Regeneron’s drug discovery and development approach.”
“By combining our expertise in protein detection and measurement with RGC's expertise in genetics and vast data stores, we expect this agreement to unlock the potential of our offerings to enable proteomics at scale, thereby allowing customers like RGC to achieve extraordinary new insights into disease biology and pave the way for more effective treatment options,” said Jon Heimer, CEO of Olink. “We are proud to work with and support Regeneron Genetics Center, a leader in genetics research, to bring together the power of protein and genetic data to drive precision medicine forward.”
Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com
Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com
About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
Olink forward-looking statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
